Adalsteinn Gunnlaugsson
11 – 20 of 60
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Register data on long-term morbidity after prostate ultra-hypofractionation in the HYPO-RT-PC trial
- Contribution to journal › Published meeting abstract
-
Mark
Register data on long-term morbidity after prostate cancer radiotherapy with ultra-hypofractionated (2.5 weeks) vs conventional (8 weeks) treatment schedules
(2024) U21 Health Sciences Group 2024 Doctoral Student Forum
- Contribution to conference › Poster
-
Mark
Accuracy of gross tumour volume delineation with [68Ga]-PSMA-PET compared to histopathology for high-risk prostate cancer
- Contribution to journal › Article
-
Mark
Morbiditet från urinvägar och tarm enligt registerdata efter ultrahypofraktionerad strålbehandling för lokaliserad prostatacancer vid 10 år i HYPO-RT-PC-studien
(2024) Onkologidagarna 2024
- Contribution to conference › Poster
-
Mark
Ultrahypofractionated Radiation Therapy for Prostate Cancer Including Seminal Vesicles in the Target Volume : A Treatment-planning Study Based on the HYPO-RT-PC Fractionation Schedule
- Contribution to journal › Article
-
Mark
Evaluation of a deep learning magnetic resonance imaging reconstruction method for synthetic computed tomography generation in prostate radiotherapy
- Contribution to journal › Article
- 2023
-
Mark
MRI-only radiotherapy from an economic perspective : Can new techniques in prostate cancer treatment be cost saving?
- Contribution to journal › Article
-
Mark
Risk of prostate cancer death after radical radiotherapy with neoadjuvant and adjuvant therapy with bicalutamide or gonadotropin-releasing hormone agonists
- Contribution to journal › Article
-
Mark
Urosymphyseal fistula after pelvic radiotherapy in a tertial referral centre - a rare entity with significant comorbidity requiring multidisciplinary management
- Contribution to journal › Article
- 2022
-
Mark
A prospective phase II study of prostate-specific antigen-guided salvage radiotherapy and 68Ga-PSMA-PET for biochemical relapse after radical prostatectomy - The PROPER 1 trial
- Contribution to journal › Article
